Does chronic low-grade inflammation drive atherosclerosis by activating endothelium and promoting oxidation and immune uptake of apoB lipoproteins?

Atherosclerosis is increasingly understood not merely as a lipid-storage disease but as a chronic inflammatory process. Evidence confirms that low-grade systemic inflammation is a primary driver of the development and progression of atherosclerotic plaques, particularly in aging populations.

Clinical and effectiveness evidence

The link between chronic inflammation and atherosclerosis is well-established through clinical markers such as high-sensitivity C-reactive protein (hs-CRP).

• Predictive value: Elevated hs-CRP is a robust predictor of major adverse cardiovascular events (MACE), often independently of LDL cholesterol levels. Research into "residual inflammatory risk" shows that individuals with low LDL but high hs-CRP remain at significant risk for heart disease.
• Intervention studies: Large-scale clinical trials (e.g., CANTOS using canakinumab and COLCOT using colchicine) have demonstrated that targeting inflammatory pathways directly can reduce cardiovascular event rates by 15–31%, providing definitive proof that inflammation is a causal factor in disease progression.

Mechanistic explanations

Inflammation promotes atherosclerosis through a series of coordinated molecular and cellular events:

• Endothelial activation: Pro-inflammatory cytokines like TNF-α and IL-1β trigger the NF-κB signaling pathway in the vascular lining. This causes the endothelium to express cell adhesion molecules (ICAM-1, VCAM-1, and E-selectin) which act as "hooks" to capture circulating immune cells.
• Lipid modification: Inflammation increases the activity of enzymes such as myeloperoxidase (MPO) and NADPH oxidase. These enzymes produce reactive species (like hypochlorous acid) that oxidize the apolipoprotein B-100 (apoB) component of LDL and Lp(a), turning native lipoproteins into highly reactive oxidized forms (oxLDL).
• Immune uptake and foam cells: Unlike native LDL, oxidized apoB lipoproteins are not recognized by regular LDL receptors. Instead, they are aggressively internalized by macrophage scavenger receptors (such as CD36 and SR-A). Because this uptake is unregulated, macrophages become engorged with cholesterol, transforming into "foam cells"—the hallmark of atherosclerotic plaque.

Clinical implications

For a 60-year-old male, managing systemic inflammation is as critical as managing lipid profiles.

• Plaque stability: Inflammation does not just increase plaque size; it destabilizes existing plaques by promoting the formation of a thin fibrous cap (thin-cap fibroatheroma), which is more prone to rupture and causing acute events like myocardial infarction.
• Synergy with age: In older adults, factors like abdominal obesity can amplify this low-grade inflammatory state, accelerating the recruitment of monocytes and the subsequent oxidative modification of lipoproteins within the vessel wall.

Bottom line

Chronic low-grade inflammation is a validated driver of atherosclerosis. It initiates the disease by activating the vascular endothelium to recruit immune cells and accelerates plaque formation by promoting the oxidation and scavenger-mediated uptake of apoB-containing lipoproteins.